Special Pharmaceutical Benefits Program Adds Two Drugs to Program ...
Yahoo News (press release) - Aug 1, 2003
... Pennsylvania Public Welfare Secretary Estelle B. Richman today announced the
addition of Fuzeon (enfuvirtide) for the treatment of HIV/AIDS and Abilify ...

Submits New Drug
Mind Horizons, TX - Jul 31, 2003
have announced that a Supplemental New Drug Application (sNDA) for ABILIFY™ (aripiprazole)
for the treatment of acute mania in patients with bipolar disorder ...

But Dip in US
Mind Horizons, TX - Jul 31, 2003
... $398 million, while US sales increased only two percent to $648 million, most likely
due to stiff competition from Bristol-Myers Squibb Co.'s BMY.N new Abilify ...

TEXT-S&P cuts Bristol-Myers Squibb senior unsecured rtg
Reuters, UK - Jul 29, 2003
... The outlook is negative. "Although Bristol-Myers' new schizophrenia treatment, Abilify,
is off to a strong start, the rating actions are because of Standard & ...

Schaeffer's Option Activity Watch Features BMY, IMCL, XOM
Yahoo News (press release) - Jul 29, 2003
... Sales for the quarter soared 22 percent on a strong performance from its new schizophrenia
drug Abilify, as well as increased worldwide sales of Pravachol and ...

Schaeffer's Option Activity Watch Features BMY, IMCL, XOM
Stock World, Germany - Jul 29, 2003
... Sales for the quarter soared 22 percent on a strong performance from its new schizophrenia
drug Abilify, as well as increased worldwide sales of Pravachol and ...

AT&T profit tops forecast
San Mateo County Times, CA - Jul 25, 2003
... expected. Demand for Bristol-Myers's Abilify schizophrenia drug helped
the New York-based company almost double second-quarter profit. ...

AT&T profit tops forecast
Oakland Tribune, CA - Jul 25, 2003
... expected. Demand for Bristol-Myers's Abilify schizophrenia drug helped
the New York-based company almost double second-quarter profit. ...

Bristol-Myers earnings rise 83% to $878 million in 2Q
Baltimore Sun, MD - Jul 25, 2003
... Bristol-Myers is rolling out new products, such as Abilify for schizophrenia
and Reyataz for AIDS, as revenue from other medicines is lost to generic ...

Mortgages Near 6 Percent
Washington Post, DC - Jul 24, 2003
... Bristol-Myers Squibb said second-quarter earnings rose 83 percent, to $878 million,
helped by the early success of Abilify, a schizophrenia drug, and increased ...

Bristol Myers profits up 63 percent in 2Q
Seattle Post Intelligencer, WA - Jul 24, 2003
... Peter Dolan said demand for the pharmaceutical company's prescription products "continues
to be robust." He expressed particular confidence about Abilify, the ...

Lilly posts 5 percent earnings gain in 2Q
Seattle Post Intelligencer, WA - Jul 24, 2003
... That compared with 2 percent growth in the United States, where Zyprexa faces competition
from newer anti-psychotics, including Bristol-Myers Squibb's Abilify ...

Lilly Posts 5 Percent Earnings Gain in 2Q
ABC News - Jul 24, 2003
... That compared with 2 percent growth in the United States, where Zyprexa faces competition
from newer anti-psychotics, including Bristol-Myers Squibb's Abilify ...

Bristol-Myers second-quarter profits up 83 percent, but patent ...
San Francisco Chronicle, CA - Jul 24, 2003
... told analysts that demand for the company's prescription products "continues to
be robust." He expressed particular confidence in schizophrenia drug Abilify ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Austin American Statesman, TX - Jul 24, 2003
... That compared with 2 percent growth in the United States, where Zyprexa faces competition
from newer anti-psychotics, including Bristol-Myers Squibb's Abilify ...

Lilly Posts 5 Percent Earnings Gain in 2Q
Atlanta Journal Constitution, GA - Jul 24, 2003
... That compared with 2 percent growth in the United States, where Zyprexa faces competition
from newer anti-psychotics, including Bristol-Myers Squibb's Abilify ...

Bristol-Myers Profit Beats Dismal '02
Washington Post, DC - Jul 24, 2003
... Earnings also got a lift from its new schizophrenia treatment, Abilify,
which is stealing sales from rival Eli Lilly and Co.'s Zyprexa. ...

Eli Lilly Profits Helped by Zyprexa
MSN Money - Jul 24, 2003
... 45 percent to $398 million, while US sales edged up only 2 percent to $648 million
on stiff competition from Bristol-Myers Squibb Co.'s (BMY) new Abilify ...

Eli Lilly Profits Helped by Zyprexa
Reuters, UK - Jul 24, 2003
... 45 percent to $398 million, while US sales edged up only 2 percent to $648 million
on stiff competition from Bristol-Myers Squibb Co.'s BMY.N new Abilify ...

Bristol-Myers Profit Beats Dismal '02
Reuters, UK - Jul 24, 2003
... Earnings also got a lift from its new schizophrenia treatment, Abilify,
which is stealing sales from rival Eli Lilly and Co.'s LLY.N Zyprexa. ...

Bristol-Myers Profit Beats Dismal '02
MSN Money - Jul 24, 2003
... Earnings also got a lift from its new schizophrenia treatment, Abilify,
which is stealing sales from rival Eli Lilly and Co.'s (LLY) Zyprexa. ...

Bristol Myers Profits Up 63 Percent in 2Q
Washington Post, DC - Jul 24, 2003
... Peter Dolan said demand for the pharmaceutical company's prescription products "continues
to be robust." He expressed particular confidence about Abilify, the ...

Bristol-Myers second-quarter profit shoots up 83 percent
Wichita Eagle, KS - Jul 24, 2003
... Peter Dolan said demand for the pharmaceutical company's prescription products "continues
to be robust." He expressed particular confidence about Abilify, the ...

Drugmakers Deliver Profits, Shares Rise
FOX News - Jul 24, 2003
... Bristol-Myers sales representatives have been boasting that its drug, called Abilify
(search), does not cause weight gain that can possibly lead to diabetes. ...

Bristol Myers Profits Up 63 Percent in 2Q
Austin American Statesman, TX - Jul 24, 2003
... Peter Dolan said demand for the pharmaceutical company's prescription products
``continues to be robust.'' He expressed particular confidence about Abilify ...

Bristol Myers Profits Up 63 Percent in 2Q
Atlanta Journal Constitution, GA - Jul 24, 2003
... Peter Dolan said demand for the pharmaceutical company's prescription products
``continues to be robust.'' He expressed particular confidence about Abilify ...

Bristol-Myers second-quarter profit shoots up 83 percent
Akron Beacon Journal, OH - Jul 24, 2003
... Peter Dolan said demand for the pharmaceutical company's prescription products "continues
to be robust." He expressed particular confidence about Abilify, the ...

Bristol-Myers second-quarter profit shoots up 83 percent
Miami Herald, FL - Jul 24, 2003
... Peter Dolan said demand for the pharmaceutical company's prescription products "continues
to be robust." He expressed particular confidence about Abilify, the ...

Drugmakers Deliver Profits, Shares Rise
Reuters, UK - Jul 24, 2003
... Bristol-Myers sales representatives have been boasting that its drug, called
Abilify, does not cause weight gain that can possibly lead to diabetes. ...

Bristol-Myers second-quarter profit shoots up 83 percent
Kansas City Star, MO - Jul 24, 2003
... Peter Dolan said demand for the pharmaceutical company's prescription products "continues
to be robust." He expressed particular confidence about Abilify, the ...

Bristol-Myers second-quarter profit shoots up 83 percent
Fort Wayne News Sentinel, IN - Jul 24, 2003
... Peter Dolan said demand for the pharmaceutical company's prescription products "continues
to be robust." He expressed particular confidence about Abilify, the ...

Bristol-Myers Second-Quarter Net Surges on Heart Drug (Update4)
Bloomberg - Jul 24, 2003
The company is rolling out new products, such as Abilify for schizophrenia and Reyataz
for AIDS, as revenue from other medicines is lost to generic competition ...

Big drugmakers deliver higher profits, shares rise
Forbes - Jul 24, 2003
... Bristol-Myers sales representatives have been boasting that its drug, called
Abilify, does not cause weight gain that can possibly lead to diabetes. ...

Big drugmakers deliver higher profits, shares rise
Reuters, UK - Jul 24, 2003
... Bristol-Myers sales representatives have been boasting that its drug, called
Abilify, does not cause weight gain that can possibly lead to diabetes. ...

UPDATE 3-Eli Lilly quarterly profit up, helped by Zyprexa
Reuters, UK - Jul 24, 2003
... 45 percent to $398 million, while US sales edged up only 2 percent to $648 million
on stiff competition from Bristol-Myers Squibb Co.'s BMY.N new Abilify ...

Bristol sees new drugs offsetting patent-loss pain
Forbes - Jul 24, 2003
Company officials told analysts in a conference call that they expect the stronger
sales to come from Abilify for schizophrenia and HIV treatment Reyataz. ...

Bristol-Myers second-quarter profit shoots up 83 percent
Newsday - Jul 24, 2003
... The company's Abilify, a schizophrenia drug which was introduced in the
US in November 2002, recorded revenue of $65 million in the quarter. ...

Bristol-Myers 2Q Profit Up 83 Percent
Newsday - Jul 24, 2003
... The company's Abilify, a schizophrenia drug which was introduced in the
US in November 2002, recorded revenue of $65 million in the quarter. ...

Bristol-Myers 2Q Profit Up 83 Percent
San Jose Mercury News, CA - Jul 24, 2003
... The company's Abilify, a schizophrenia drug which was introduced in the
US in November 2002, recorded revenue of $65 million in the quarter. ...

Bristol-Myers 2Q Profit Up 83 Percent
Miami Herald, FL - Jul 24, 2003
... The company's Abilify, a schizophrenia drug which was introduced in the
US in November 2002, recorded revenue of $65 million in the quarter. ...

Bristol-Myers 2Q Profit Up 83 Percent
Times Daily, AL - Jul 24, 2003
... The company's Abilify, a schizophrenia drug which was introduced in the
US in November 2002, recorded revenue of $65 million in the quarter. ...

Bristol-Myers 2Q Profit Up 83 Percent
Austin American Statesman, TX - Jul 24, 2003
... The company's Abilify, a schizophrenia drug which was introduced in the
US in November 2002, recorded revenue of $65 million in the quarter. ...

Bristol-Myers 2Q Profit Up 83 Percent
Wichita Eagle, KS - Jul 24, 2003
... The company's Abilify, a schizophrenia drug which was introduced in the
US in November 2002, recorded revenue of $65 million in the quarter. ...

Bristol-Myers 2Q Profit Up 83 Percent
Kansas City Star, MO - Jul 24, 2003
... The company's Abilify, a schizophrenia drug which was introduced in the
US in November 2002, recorded revenue of $65 million in the quarter. ...

Bristol-Myers 2Q Profit Up 83 Percent
Sarasota Herald-Tribune, FL - Jul 24, 2003
... The company's Abilify, a schizophrenia drug which was introduced in the
US in November 2002, recorded revenue of $65 million in the quarter. ...

Bristol-Myers 2Q Profit Up 83 Percent
Atlanta Journal Constitution, GA - Jul 24, 2003
... The company's Abilify, a schizophrenia drug which was introduced in the
US in November 2002, recorded revenue of $65 million in the quarter. ...

Bristol-Myers 2Q Profit Up 83 Percent
Fort Wayne News Sentinel, IN - Jul 24, 2003
... The company's Abilify, a schizophrenia drug which was introduced in the
US in November 2002, recorded revenue of $65 million in the quarter. ...

Bristol-Myers 2Q Profit Up 83 Percent
Akron Beacon Journal, OH - Jul 24, 2003
... The company's Abilify, a schizophrenia drug which was introduced in the
US in November 2002, recorded revenue of $65 million in the quarter. ...

Lilly, Bristol Post Higher Profits; AstraZeneca Boosts Forecast
Bloomberg - Jul 24, 2003
Demand for Bristol-Myers's Abilify schizophrenia treatment helped
the New York-based company almost double second-quarter profit. ...

Bristol-Myers Results Shine
Smart Money - Jul 24, 2003
(BMY) said second-quarter net income jumped 83% on early success of schizophrenia
treatment Abilify and continued growth of other key drugs. ...

RPT-UPDATE 1-Bristol-Myers earnings beat dismal 2002 results
Forbes - Jul 24, 2003
... Earnings got a hefty boost from the company's new schizophrenia treatment, Abilify,
which is stealing sales from rival Eli Lilly and Co.'s (nyse: LLY - news ...

Bristol-Myers earnings beat dismal 2002 results
USA Today - Jul 24, 2003
... Earnings got a hefty boost from the company's new schizophrenia treatment, Abilify,
which is stealing sales from rival Eli Lilly's medicine Zyprexa.

Eli Lilly Profit Rises, Helped by Zyprexa
FOX News - Jul 24, 2003
... 45 percent to $398 million, while US sales edged up only 2 percent to $648 million
on stiff competition from Bristol-Myers Squibb Co.'s (BMY) new Abilify ...

RPT-UPDATE 1-Bristol-Myers earnings beat dismal 2002 results
Reuters, UK - Jul 24, 2003
... Earnings got a hefty boost from the company's new schizophrenia treatment, Abilify,
which is stealing sales from rival Eli Lilly and Co.'s LLY.N medicine ...

Bristol Myers 2Q rises
CNN - Jul 24, 2003
... Earnings got a hefty boost from the company's new schizophrenia treatment, Abilify,
which is stealing sales from rival Eli Lilly and Co.'s medicine Zyprexa.

Eli Lilly Profit Rises, Helped by Zyprexa
Washington Post, DC - Jul 24, 2003
... jumped 45 percent to $398 million, while US sales edged up only 2 percent to $648
million on stiff competition from Bristol-Myers Squibb Co.'s new Abilify ...

Eli Lilly Profit Rises, Helped by Zyprexa
MSN Money - Jul 24, 2003
... 45 percent to $398 million, while US sales edged up only 2 percent to $648 million
on stiff competition from Bristol-Myers Squibb Co.'s (BMY) new Abilify ...

Eli Lilly Profit Rises, Helped by Zyprexa
Reuters, UK - Jul 24, 2003
... 45 percent to $398 million, while US sales edged up only 2 percent to $648 million
on stiff competition from Bristol-Myers Squibb Co.'s BMY.N new Abilify ...

Bristol-Myers Earnings Beat Dismal '02
Reuters, UK - Jul 24, 2003
... Earnings got a hefty boost from the company's new schizophrenia treatment, Abilify,
which is stealing sales from rival Eli Lilly and Co.'s LLY.N medicine ...

Bristol-Myers Squibb Announces Second Quarter and Six Months ...
Yahoo News (press release) - Jul 24, 2003
Fully diluted earnings per share for the quarter were $.45. "Company sales and earnings
this quarter were boosted by the early success of ABILIFY(TM), as well ...

Tapping the pipeline
Newark Star Ledger, NJ - Jul 23, 2003
... Since Palmer was hired, Bristol-Myers has started selling Abilify, a treatment for
schizophrenia, and more recently, it secured regulatory approval for Reyataz ...

Health sense: Treatment can have unwanted effect
Minneapolis Star Tribune, MN - Jul 20, 2003
... to suicide. Fortunately, several newer drugs, including Geodon and
the recently approved Abilify, don't cause weight gain. Cancer ...

Eli Lilly: firmer footing for Zyprexa
UK Comment Wire, UK - Jul 17, 2003
... market. Bristol-Myers Squibb [BMY], in particular, represents a major
threat to Lilly's market share with its novel drug Abilify. ...

FDA expands use of Zyprexa
Indianapolis Star, IN - Jul 16, 2003
... The approval comes as Zyprexa faces increasing competition from newer antipsychotics,
including Bristol-Myers Squibb's Abilify and Pfizer's Geodon. ...

Healthcast: Autism; Breast Cancer; Zyprexa
INDYchannel.com, IN - Jul 15, 2003
... The approval comes as Zyprexa faces increasing competition from newer anti-psychotics,
including Bristol-Myers Squibb's Abilify and Pfizer's Geodon. ...

FDA gives Lilly's best-selling drug approval for expanded use
Akron Beacon Journal, OH - Jul 15, 2003
... The approval comes as Zyprexa faces increasing competition from newer anti-psychotics,
including Bristol-Myers Squibb's Abilify and Pfizer's Geodon. ...

FDA gives Lilly's best-selling drug approval for expanded use
Kansas City Star, MO - Jul 15, 2003
... The approval comes as Zyprexa faces increasing competition from newer anti-psychotics,
including Bristol-Myers Squibb's Abilify and Pfizer's Geodon. ...

FDA gives Lilly's best-selling drug approval for expanded use
Fort Wayne News Sentinel, IN - Jul 15, 2003
... The approval comes as Zyprexa faces increasing competition from newer anti-psychotics,
including Bristol-Myers Squibb's Abilify and Pfizer's Geodon. ...

FDA gives Lilly's best-selling drug approval for expanded use
Miami Herald, FL - Jul 15, 2003
... The approval comes as Zyprexa faces increasing competition from newer anti-psychotics,
including Bristol-Myers Squibb's Abilify and Pfizer's Geodon. ...

FDA gives Lilly's best-selling drug approval for expanded use
Wichita Eagle, KS - Jul 15, 2003
... The approval comes as Zyprexa faces increasing competition from newer anti-psychotics,
including Bristol-Myers Squibb's Abilify and Pfizer's Geodon. ...

Taking health risks for the sake of looks
Boston Globe, MA - Jul 15, 2003
... a matter of vanity; it's a serious threat to a person's general health.'' Fortunately,
several newer drugs, including Geodon and the recently approved Abilify ...

Johnson & Johnson CEO May Buy Rivals to Spur Growth (Update2)
Bloomberg - Jul 14, 2003
... Bristol-Myers Squibb Co. has also introduced a schizophrenia pill, Abilify,
that competes with Johnson & Johnson's Risperdal medicine. ...

Johnson & Johnson CEO May Buy Rivals to Spur Growth (Update1)
Bloomberg - Jul 14, 2003
... Bristol-Myers Squibb Co. has also introduced a schizophrenia pill, Abilify,
that competes with Johnson & Johnson's Risperdal medicine. ...

Johnson & Johnson's Weldon May Buy Rivals as Cypher Loses Edge
Bloomberg - Jul 13, 2003
... Bristol-Myers Squibb Co. has also introduced a schizophrenia pill, Abilify,
that competes with Johnson & Johnson's Risperdal schizophenia medicine. ...

Drug earnings a pill for investors
Newark Star Ledger, NJ - Jul 12, 2003
... Analysts will be watching sales of Abilify, a schizophrenia drug approved last
November. Bristol-Myers has its research headquarters in New Jersey. ...

THE STOCKPICKERS
CBS MarketWatch - Jul 9, 2003
... Two new drugs to watch are Abilify, an antipsychotic likely to give similar entries
from Eli Lilly (LLY: news, chart, profile) and Johnson & Johnson (JNJ: news ...

[Click here to JOIN and get our WEEKLY newsletter!!]